IP77-11: Dissecting the tumor microenvironment of advanced urothelial carcinoma pre and post enfortumab vedotin ± pembrolizumab
Monday, May 18, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
147A
Abstract
Log in
See all the content and easy-to-use features by logging in or registering!